Phase 3 ePHex Study: OxThera Reports Results
Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.
Want our news in your inbox every Monday morning? You can!